XBI
State Street SPDR S&P Biotech ETF (XBI)
XBI (State Street SPDR S&P Biotech ETF) charges a 0.35% expense ratio. On a $10,000 investment that is about $35.00 per year in fund fees, or about $350 per year on $100,000. The fee is deducted automatically from the fund's value, not billed separately. See how expense ratios work →
Performance (data as of Jul 26, 2026): YTD +29.8% · 1-year +73.8% · 3-year +21.7% annualized · 5-year +3.9% annualized. Dividend yield 0.36%. $10.7B in assets. Past performance does not guarantee future results.
SPDR S&P Biotech ETF: about 130 biotech companies, equal-weighted, at 0.35%. Equal weighting is the defining feature: small and mid-cap biotechs get the same representation as large names, which means more exposure to binary drug approval events and more volatility than market-cap weighted IBB. XBI fell more than 60% from its 2021 peak to its 2022 trough.
✓ Who it's actually for
! Know this before you buy
Editorial opinion based on documented fund characteristics, not personalized investment advice. ETF BFF is not a registered investment advisor.
📖 New to ETF fact sheets? Here's how to use this page:
📈 Performance history
Annualized where notedReturns are price-based and exclude dividend reinvestment. Total return will typically be higher by approximately the fund's annual yield. Past performance does not guarantee future results.
How does this ETF stack up against the competition?
⚖️ Compare side by side →🛡️ Risk and volatility
✅ Before you buy this ETF
Check these boxes before buying. Good investing habits matter more than picking the right fund.
❓ Questions people actually ask about this ETF
-
XBI's expense ratio is 0.35% per year. On a $10,000 investment, that is roughly $35.00 per year in fund fees, automatically deducted from the fund's NAV, not billed separately. What expense ratios cover, and what a good one looks like →
-
SPDR S&P Biotech ETF: about 130 biotech companies, equal-weighted, at 0.35%. Equal weighting is the defining feature: small and mid-cap biotechs get the same representation as large names, which means more exposure to binary drug approval events and more volatility than market-cap weighted IBB. XBI fell more than 60% from its 2021 peak to its 2022 trough. Past performance does not guarantee future results. Educational only, not personalized investment advice. ETF BFF is not a registered investment advisor.
-
XBI returned +73.8% over the trailing 12 months. Past performance does not guarantee future results. ETF returns fluctuate with market conditions. Educational only, not personalized investment advice.
-
XBI (State Street SPDR S&P Biotech ETF) has $10.7B in assets under management. AUM is a measure of fund size and liquidity. Larger funds generally have tighter bid-ask spreads and are less likely to close. It is not a measure of quality or expected returns.
-
XBI has a trailing 12-month dividend yield of 0.36%. ETF dividends are paid to shareholders based on distributions collected from the underlying holdings. Dividend payments are not guaranteed and can vary each quarter based on fund holdings and market conditions. Educational only, not personalized investment advice.
-
Use the ETF BFF comparison tool at etfbff.com/research/compare/ to run a side-by-side analysis of XBI against similar ETFs, covering expense ratios, holdings overlap, performance history, and our plain-English verdict on which one fits your goals.
All answers are educational and general in nature, not personal financial advice. Always verify data with the fund issuer and do your own research before investing.